尿毒症皮肤瘙痒治疗新药difelikefalin的药理作用和临床评价  

Pharmacological action and clinical evaluation of difelikefalin, a new drug for the treatment of uremic pruritus

作　　者：蔡金蕊 李春杏 刘丽艳 王羽峤 马晓东 刘桦[1] Cai Jinrui;Li Chunxing;Liu Liyan;Wang Yuqiao;Ma Xiaodong;Liu Hua(Department of Pharmacy,Aerospace Center Hospital,Beijing 100049,China)

机构地区：[1]航天中心医院药剂科,北京100049

出　　处：《中国基层医药》2022年第11期1757-1760,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：尿毒症皮肤瘙痒是困扰血液透析或腹膜透析终末期肾脏患者的皮肤并发症之一,由于具体发病机制不明确,国际上没有统一的治疗方案。2021年8月美国食品药品监督管理局(FDA)批准difelikefalin(商品名Korsuva)上市,用于治疗接受血液透析的成人中重度慢性肾病相关性皮肤瘙痒。研究显示difelikefalin可以明显降低瘙痒强度、改善睡眠和瘙痒相关生活质量,推荐剂量为0.5μg/kg,耐受性和安全性较好,本研究就其药理作用、药动学、临床疗效及安全性等作一综述。Uremic pruritus is one of the skin complications that perplex patients with end-stage renal disease undergoing hemodialysis or peritoneal dialysis.Because the specific pathogenesis is not clear,there is no unified treatment plan in the world.In August 2021,the US Food and Drug Administration approved the use of difelikefalin(under the trade name Korsuva)for the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.Studies have shown that difelikefalin can remarkably reduce the intensity of pruritus and improve sleep and pruritus-related quality of life.The recommended dose of difelikefalin is 0.5μg/kg,and difelikefalin is well tolerated and has high safety.This paper reviews the pharmacological effects,pharmacokinetics,clinical efficacy and safety of difelikefalin.

关 键 词：尿毒症 瘙痒症 皮肤 药理作用 药物评价 病人安全 综述 

分 类 号：R969[医药卫生—药理学]